Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
176 hedge funds and large institutions have $1.23B invested in Acorda Therapeutics in 2015 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 50 reducing their positions, and 21 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 50
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
4% more funds holding
Funds holding: 170 → 176 (+6)
19% less capital invested
Capital invested by funds: $1.51B → $1.23B (-$282M)
75% less call options, than puts
Call options by funds: $2.15M | Put options by funds: $8.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.9M |
| 3 |
SCM
Scopia Capital Management
New York
|
+$18.3M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$16.5M |
| 5 |
Millennium Management
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$56.1M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$22.7M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$13.7M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$9.87M |
| 5 |
Renaissance Technologies
New York
|
-$9.48M |
ACOR Hedge Fund Activity: Q3 2015 in Review
176 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2015, worth a combined $1.23B — down 19% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACOR positions and 21 closed out — a net gain of 7 holders — while 69 added to existing stakes and 50 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $35M. The largest seller was UBS AM, cutting an estimated $56.1M.
- 176 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2015, up from 170 in Q2 2015.
- Funds reported $1.23B of Acorda Therapeutics stock for Q3 2015, down 19% quarter-over-quarter.
- 28 funds opened new Acorda Therapeutics positions in Q3 2015 and 21 closed out, a net change of +7 holders.
- The largest Acorda Therapeutics buyer in Q3 2015 was Point72 Asset Management, an estimated $35M added.
- The largest Acorda Therapeutics seller in Q3 2015 was UBS AM, an estimated $56.1M sold.
Based on aggregated 13F filings for Q3 2015.